Viewing Study NCT06626074



Ignite Creation Date: 2024-10-26 @ 3:41 PM
Last Modification Date: 2024-10-26 @ 3:41 PM
Study NCT ID: NCT06626074
Status: NOT_YET_RECRUITING
Last Update Posted: None
First Post: 2024-10-01

Brief Title: Exploratory Study of MRI Biomarkers of NASH
Sponsor: None
Organization: None

Study Overview

Official Title: Exploratory Study of MRI Biomarkers of NASH
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: IRM-NASH
Brief Summary: Metabolic steatosis disease NAFLD is a rapidly growing disease in the world particularly in industrialized countries

NAFLD is defined by the presence of fatty liver disease This is a reversible phenomenon that can be estimated by non-invasive means such as ultrasound Non-invasive quantification on the other hand requires MRI

Nonalcoholic steatohepatitis NASH is the aggressive form of the disease that promotes the accumulation of fibrosis in the liver which can progress to cirrhosis and its complications

Currently there is no non-invasive biomarker of NASH and the diagnosis is based solely on liver biopsy

There is therefore a need for non-invasive biomarkers of NASH in patients with steatosis to diagnose NASH without the use of liver biopsy
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None